Loading...
Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial
Andrew, R. P. Richard, J. Silvia, C. Fotis, P. Christina, Y. James, D. Matthew, B. Michael, S. Umair, T. K. Stacey, C.
Andrew, R. P.
Richard, J.
Silvia, C.
Fotis, P.
Christina, Y.
James, D.
Matthew, B.
Michael, S.
Umair, T. K.
Stacey, C.
Citations
Altmetric:
Abstract
None
Authors
Andrew, R. P.
Richard, J.
Silvia, C.
Fotis, P.
Christina, Y.
James, D.
Matthew, B.
Michael, S.
Umair, T. K.
Stacey, C.
Melanie, O.
Ke, L.
Sarah, E. C.
Geetha, M.
Nagesh, K.
Helen, M.
Bloor, Adrian
Anna, S.
Andrew, D.
Claire, D.
Christopher, F.
Ben, K.
Renata, W.
Scott, M.
Christopher, P. F.
Peter, H.
Richard, J.
Silvia, C.
Fotis, P.
Christina, Y.
James, D.
Matthew, B.
Michael, S.
Umair, T. K.
Stacey, C.
Melanie, O.
Ke, L.
Sarah, E. C.
Geetha, M.
Nagesh, K.
Helen, M.
Bloor, Adrian
Anna, S.
Andrew, D.
Claire, D.
Christopher, F.
Ben, K.
Renata, W.
Scott, M.
Christopher, P. F.
Peter, H.
Description
Date
2020
Publisher
Collections
Files
Loading...
FROM CORE
Adobe PDF, 722.32 KB
Keywords
Type
Article
Citation
Andrew RP, Richard J, Silvia C, Fotis P, Christina Y, James D, et al. Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial. Haematologica. 2020;105(12):2868-71.